Cargando…
The effectiveness of colostral antibodies for preventing bovine leukemia virus (BLV) infection in vitro
BACKGROUND: Bovine leukemia virus (BLV) is the causative agent of enzootic bovine leukosis (EBL). The incidence of EBL in Japan is increasing annually; and the cases of EBL in cattle younger than 2 years old has been reported. Therefore, it is vital to find a method to control BLV infection, especia...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311012/ https://www.ncbi.nlm.nih.gov/pubmed/30594182 http://dx.doi.org/10.1186/s12917-018-1724-5 |
_version_ | 1783383534911619072 |
---|---|
author | Konishi, Misako Ishizaki, Hiroshi Kameyama, Ken-ichiro Murakami, Kenji Yamamoto, Takehisa |
author_facet | Konishi, Misako Ishizaki, Hiroshi Kameyama, Ken-ichiro Murakami, Kenji Yamamoto, Takehisa |
author_sort | Konishi, Misako |
collection | PubMed |
description | BACKGROUND: Bovine leukemia virus (BLV) is the causative agent of enzootic bovine leukosis (EBL). The incidence of EBL in Japan is increasing annually; and the cases of EBL in cattle younger than 2 years old has been reported. Therefore, it is vital to find a method to control BLV infection, especially in young calves. In this study, to evaluate the protective ability of colostral antibodies against BLV infection, as well as the potential for BLV infection mediated by colostrum/milk, we investigated temporal fluctuations in the anti-BLV antibody titer and BLV proviral load (PVL) in colostrum/milk and peripheral blood of six infected dams during lactation. The association between PVL and antibody titer in colostrum and peripheral blood was then investigated using samples from a further twenty-seven cattle. Antibody concentrations were measured with a Syncytium-induction Inhibition Assay using colostral/milk whey and serum. PVL in peripheral blood and colostrum was measured by real-time PCR. RESULTS: Colostral antibodies showed high inhibitory activity until day 3 of lactation. The antibody titer and PVL in peripheral blood showed lesser changes than those in colostrum/milk throughout lactation. The colostral antibody titer was significantly higher than the serum antibody titer in all samples, whereas the colostrum PVL was significantly lower than the blood PVL. The blood PVL showed a significant correlation with serum antibody titer, colostrum PVL, and colostral antibody titer. However, there were no major correlations between the serum and colostral antibody titers. CONCLUSIONS: This is the first report investigating the temporal changes in colostral antibody titer in terms of inhibiting BLV infection in vitro. The results of antibody detection by Syncytium-induction Inhibition Assay suggested that the protective activity of the colostral antibodies against BLV infection would be conferred by anti-BLV gp51 antibody. The high antibody titer of colostral whey suggests that colostral whey could be a potential source of antibodies with a low risk of infection in neonatal calves. |
format | Online Article Text |
id | pubmed-6311012 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63110122019-01-07 The effectiveness of colostral antibodies for preventing bovine leukemia virus (BLV) infection in vitro Konishi, Misako Ishizaki, Hiroshi Kameyama, Ken-ichiro Murakami, Kenji Yamamoto, Takehisa BMC Vet Res Research Article BACKGROUND: Bovine leukemia virus (BLV) is the causative agent of enzootic bovine leukosis (EBL). The incidence of EBL in Japan is increasing annually; and the cases of EBL in cattle younger than 2 years old has been reported. Therefore, it is vital to find a method to control BLV infection, especially in young calves. In this study, to evaluate the protective ability of colostral antibodies against BLV infection, as well as the potential for BLV infection mediated by colostrum/milk, we investigated temporal fluctuations in the anti-BLV antibody titer and BLV proviral load (PVL) in colostrum/milk and peripheral blood of six infected dams during lactation. The association between PVL and antibody titer in colostrum and peripheral blood was then investigated using samples from a further twenty-seven cattle. Antibody concentrations were measured with a Syncytium-induction Inhibition Assay using colostral/milk whey and serum. PVL in peripheral blood and colostrum was measured by real-time PCR. RESULTS: Colostral antibodies showed high inhibitory activity until day 3 of lactation. The antibody titer and PVL in peripheral blood showed lesser changes than those in colostrum/milk throughout lactation. The colostral antibody titer was significantly higher than the serum antibody titer in all samples, whereas the colostrum PVL was significantly lower than the blood PVL. The blood PVL showed a significant correlation with serum antibody titer, colostrum PVL, and colostral antibody titer. However, there were no major correlations between the serum and colostral antibody titers. CONCLUSIONS: This is the first report investigating the temporal changes in colostral antibody titer in terms of inhibiting BLV infection in vitro. The results of antibody detection by Syncytium-induction Inhibition Assay suggested that the protective activity of the colostral antibodies against BLV infection would be conferred by anti-BLV gp51 antibody. The high antibody titer of colostral whey suggests that colostral whey could be a potential source of antibodies with a low risk of infection in neonatal calves. BioMed Central 2018-12-29 /pmc/articles/PMC6311012/ /pubmed/30594182 http://dx.doi.org/10.1186/s12917-018-1724-5 Text en © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Konishi, Misako Ishizaki, Hiroshi Kameyama, Ken-ichiro Murakami, Kenji Yamamoto, Takehisa The effectiveness of colostral antibodies for preventing bovine leukemia virus (BLV) infection in vitro |
title | The effectiveness of colostral antibodies for preventing bovine leukemia virus (BLV) infection in vitro |
title_full | The effectiveness of colostral antibodies for preventing bovine leukemia virus (BLV) infection in vitro |
title_fullStr | The effectiveness of colostral antibodies for preventing bovine leukemia virus (BLV) infection in vitro |
title_full_unstemmed | The effectiveness of colostral antibodies for preventing bovine leukemia virus (BLV) infection in vitro |
title_short | The effectiveness of colostral antibodies for preventing bovine leukemia virus (BLV) infection in vitro |
title_sort | effectiveness of colostral antibodies for preventing bovine leukemia virus (blv) infection in vitro |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311012/ https://www.ncbi.nlm.nih.gov/pubmed/30594182 http://dx.doi.org/10.1186/s12917-018-1724-5 |
work_keys_str_mv | AT konishimisako theeffectivenessofcolostralantibodiesforpreventingbovineleukemiavirusblvinfectioninvitro AT ishizakihiroshi theeffectivenessofcolostralantibodiesforpreventingbovineleukemiavirusblvinfectioninvitro AT kameyamakenichiro theeffectivenessofcolostralantibodiesforpreventingbovineleukemiavirusblvinfectioninvitro AT murakamikenji theeffectivenessofcolostralantibodiesforpreventingbovineleukemiavirusblvinfectioninvitro AT yamamototakehisa theeffectivenessofcolostralantibodiesforpreventingbovineleukemiavirusblvinfectioninvitro AT konishimisako effectivenessofcolostralantibodiesforpreventingbovineleukemiavirusblvinfectioninvitro AT ishizakihiroshi effectivenessofcolostralantibodiesforpreventingbovineleukemiavirusblvinfectioninvitro AT kameyamakenichiro effectivenessofcolostralantibodiesforpreventingbovineleukemiavirusblvinfectioninvitro AT murakamikenji effectivenessofcolostralantibodiesforpreventingbovineleukemiavirusblvinfectioninvitro AT yamamototakehisa effectivenessofcolostralantibodiesforpreventingbovineleukemiavirusblvinfectioninvitro |